| Year |
Citation |
Score |
| 2016 |
Wang Y, Cai KQ, Smith ER, Yeasky TM, Moore R, Ganjei-Azar P, Klein-Szanto AJ, Godwin AK, Hamilton TC, Xu XX. Follicle Depletion Provides A Permissive Environment for Ovarian Carcinogenesis. Molecular and Cellular Biology. PMID 27354067 DOI: 10.1128/Mcb.00202-16 |
0.599 |
|
| 2010 |
Williams RM, Flesken-Nikitin A, Ellenson LH, Connolly DC, Hamilton TC, Nikitin AY, Zipfel WR. Strategies for high-resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy. Translational Oncology. 3: 181-94. PMID 20563260 DOI: 10.1593/Tlo.09310 |
0.408 |
|
| 2009 |
Liang S, Yang N, Pan Y, Deng S, Lin X, Yang X, Katsaros D, Roby KF, Hamilton TC, Connolly DC, Coukos G, Zhang L. Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. Plos One. 4: e4295. PMID 19172191 DOI: 10.1371/Journal.Pone.0004295 |
0.439 |
|
| 2009 |
Williams SJ, Cvetkovic D, Hamilton TC. Vitamin A metabolism is impaired in human ovarian cancer Gynecologic Oncology. 112: 637-645. PMID 19110304 DOI: 10.1016/J.Ygyno.2008.11.015 |
0.438 |
|
| 2008 |
Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1291-5. PMID 18316546 DOI: 10.1158/1078-0432.Ccr-07-2238 |
0.306 |
|
| 2007 |
Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biology & Therapy. 6: 1717-25. PMID 17986851 DOI: 10.4161/Cbt.6.11.4830 |
0.376 |
|
| 2007 |
Yang WL, Cai KQ, Smedberg JL, Smith ER, Klein-Szanto A, Hamilton TC, Xu XX. A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice. The American Journal of Pathology. 170: 1325-36. PMID 17392171 DOI: 10.2353/Ajpath.2007.060769 |
0.426 |
|
| 2007 |
Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Research. 67: 2408-13. PMID 17363557 DOI: 10.1158/0008-5472.Can-06-4490 |
0.447 |
|
| 2006 |
Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. 10th Biennial Helene Harris Memorial Trust meeting. Cancer Research. 66: 2904-6. PMID 16540635 DOI: 10.1158/0008-5472.Can-05-2093 |
0.305 |
|
| 2005 |
Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O'Dwyer PJ, Johnson SW. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. British Journal of Cancer. 92: 1149-58. PMID 15726096 DOI: 10.1038/Sj.Bjc.6602447 |
0.445 |
|
| 2004 |
Cvetkovic D, Pisarcik D, Lee C, Hamilton TC, Abdollahi A. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer Gynecologic Oncology. 95: 449-455. PMID 15581945 DOI: 10.1016/J.Ygyno.2004.08.051 |
0.464 |
|
| 2004 |
Stewart SL, Querec TD, Ochman AR, Gruver BN, Bao R, Babb JS, Wong TS, Koutroukides T, Pinnola AD, Klein-Szanto A, Hamilton TC, Patriotis C. Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia. Cancer Research. 64: 8177-83. PMID 15548682 DOI: 10.1158/0008-5472.Can-04-1702 |
0.444 |
|
| 2004 |
Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC. Focus on epithelial ovarian cancer Cancer Cell. 5: 19-24. PMID 14749123 DOI: 10.1016/S1535-6108(04)00002-9 |
0.547 |
|
| 2003 |
Roland IH, Yang WL, Yang DH, Daly MB, Ozols RF, Hamilton TC, Lynch HT, Godwin AK, Xu XX. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer. 98: 2607-23. PMID 14669280 DOI: 10.1002/Cncr.11847 |
0.497 |
|
| 2003 |
Hamilton TC, Connolly DC, Nikitin AY, Garson K, Vanderhyden BC. Translational research in ovarian cancer: A must International Journal of Gynecological Cancer. 13: 220-230. PMID 14656284 DOI: 10.1111/J.1525-1438.2003.13350.X |
0.453 |
|
| 2003 |
Capo-chichi CD, Roland IH, Vanderveer L, Bao R, Yamagata T, Hirai H, Cohen C, Hamilton TC, Godwin AK, Xu XX. Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. Cancer Research. 63: 4967-77. PMID 12941822 |
0.541 |
|
| 2003 |
Abdollahi A, Gruver BN, Patriotis C, Hamilton TC. Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells. Biochemical and Biophysical Research Communications. 307: 188-97. PMID 12849999 DOI: 10.1016/S0006-291X(03)01140-9 |
0.459 |
|
| 2003 |
Garson K, Macdonald E, Dubé M, Bao R, Hamilton TC, Vanderhyden BC. Generation of tumors in transgenic mice expressing the SV40 T antigen under the control of ovarian-specific promoter 1. Journal of the Society For Gynecologic Investigation. 10: 244-50. PMID 12759154 DOI: 10.1016/S1071-5576(03)00073-X |
0.398 |
|
| 2003 |
Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Research. 63: 1389-97. PMID 12649204 |
0.377 |
|
| 2003 |
Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines Cancer Research. 63: 1311-1316. PMID 12649192 |
0.405 |
|
| 2003 |
Cvetković D, Williams SJ, Hamilton TC. Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer Clinical Cancer Research. 9: 1013-1020. PMID 12631600 |
0.409 |
|
| 2003 |
Ozols RF, Daly MB, Klein-Szanto A, Hamilton TC, Bast RC, Brewer MA. Specific keynote: chemoprevention of ovarian cancer: the journey begins Gynecologic Oncology. 88. PMID 12586088 DOI: 10.1006/Gyno.2002.6686 |
0.424 |
|
| 2003 |
Abdollahi A, Pisarcik D, Roberts D, Weinstein J, Cairns P, Hamilton TC. LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer Journal of Biological Chemistry. 278: 6041-6049. PMID 12473647 DOI: 10.1074/Jbc.M210361200 |
0.398 |
|
| 2003 |
Hamilton TC, Becker JL, Kacinski BM, Nicosia SV, Rodriquez G. Discussion: Development of Experimental Models for Ovarian Cancer Gynecologic Oncology. 88: S52-S55. DOI: 10.1006/Gyno.2002.6684 |
0.389 |
|
| 2002 |
Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. The American Journal of Pathology. 161: 1917-24. PMID 12414537 DOI: 10.1016/S0002-9440(10)64467-7 |
0.387 |
|
| 2002 |
Yang DH, Smith ER, Roland IH, Sheng Z, He J, Martin WD, Hamilton TC, Lambeth JD, Xu XX. Disabled-2 is essential for endodermal cell positioning and structure formation during mouse embryogenesis. Developmental Biology. 251: 27-44. PMID 12413896 DOI: 10.1006/Dbio.2002.0810 |
0.342 |
|
| 2002 |
Capo-Chichi CD, Smith ER, Yang DH, Roland IH, Vanderveer L, Cohen C, Hamilton TC, Godwin AK, Xu XX. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer. 95: 1802-15. PMID 12365030 DOI: 10.1002/Cncr.10870 |
0.578 |
|
| 2002 |
Yang DH, Smith ER, Cohen C, Wu H, Patriotis C, Godwin AK, Hamilton TC, Xu XX. Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity Cancer. 94: 2380-2392. PMID 12015763 DOI: 10.1002/Cncr.10497 |
0.587 |
|
| 2002 |
Pan B, Yao KS, Monia BP, Dean NM, McKay RA, Hamilton TC, O'Dwyer PJ. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): Evidence for the role of transcription factor overexpression in determining resistant phenotype Biochemical Pharmacology. 63: 1699-1707. PMID 12007573 DOI: 10.1016/S0006-2952(02)00841-9 |
0.44 |
|
| 2002 |
Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA, Hamilton TC. Activation of cancer-specific gene expression by the survivin promoter. Journal of the National Cancer Institute. 94: 522-8. PMID 11929953 DOI: 10.1093/Jnci/94.7.522 |
0.419 |
|
| 2002 |
Roberts D, Williams SJ, Cvetkovic D, Weinstein JK, Godwin AK, Johnson SW, Hamilton TC. Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. Dna and Cell Biology. 21: 11-9. PMID 11879576 DOI: 10.1089/10445490252810276 |
0.63 |
|
| 2002 |
Bao R, Selvakumaran M, Hamilton TC. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter Gynecologic Oncology. 84: 228-234. PMID 11812079 DOI: 10.1006/Gyno.2001.6490 |
0.422 |
|
| 2001 |
Hamilton TC, Johnson SW. Recent insights into drug resistance in ovarian cancer. Methods in Molecular Medicine. 39: 89-106. PMID 21340760 DOI: 10.1385/1-59259-071-3:89 |
0.469 |
|
| 2001 |
Smith ER, Capo-chichi CD, He J, Smedberg JL, Yang DH, Prowse AH, Godwin AK, Hamilton TC, Xu XX. Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinoic acid in embryonic carcinoma cells. The Journal of Biological Chemistry. 276: 47303-10. PMID 11577091 DOI: 10.1074/Jbc.M106158200 |
0.519 |
|
| 2001 |
Bingham C, Roberts D, Hamilton TC. The role of molecular biology in understanding ovarian cancer initiation and progression International Journal of Gynecological Cancer. 11: 7-11. PMID 11488996 DOI: 10.1046/j.1525-1438.2001.11(suppl.1)sup1007.x |
0.36 |
|
| 2001 |
Smith ER, Smedberg JL, Rula ME, Hamilton TC, Xu XX. Disassociation of MAPK Activation and c-Fos Expression in F9 Embryonic Carcinoma Cells following Retinoic Acid-induced Endoderm Differentiation Journal of Biological Chemistry. 276: 32094-32100. PMID 11402055 DOI: 10.1074/Jbc.M105009200 |
0.314 |
|
| 2000 |
Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochemical Pharmacology. 60: 1305-13. PMID 11008124 DOI: 10.1016/S0006-2952(00)00441-X |
0.433 |
|
| 2000 |
Bao R, Selvakumaran M, Hamilton TC. Use of a surrogate marker (Human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts Gynecologic Oncology. 78: 373-379. PMID 10985897 DOI: 10.1006/Gyno.2000.5925 |
0.373 |
|
| 1999 |
Hazelton DA, Hamilton TC. Vascular endothelial growth factor in ovarian cancer Current Oncology Reports. 1: 59-63. PMID 11122799 DOI: 10.1007/S11912-999-0011-9 |
0.399 |
|
| 1999 |
Abdollahi A, Bao R, Hamilton TC. LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein Oncogene. 18: 6477-6487. PMID 10597250 DOI: 10.1038/Sj.Onc.1203067 |
0.396 |
|
| 1999 |
Kruk PA, Godwin AK, Hamilton TC, Auersperg N. Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer Gynecologic Oncology. 73: 229-236. PMID 10329039 DOI: 10.1006/Gyno.1999.5348 |
0.604 |
|
| 1999 |
Hamilton TC, Risch HA. Re: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone [6] (multiple letters) Journal of the National Cancer Institute. 91: 650-651. PMID 10203291 DOI: 10.1093/Jnci/91.7.650 |
0.403 |
|
| 1999 |
Abdollahi A, Getts LA, Sonoda G, Miller PD, Taguchi T, Godwin AK, Testa JR, Hamilton TC. Genome Scanning Detects Amplification of the Cathepsin B Gene (CtsB) in Transformed Rat Ovarian Surface Epithelial Cells Journal of the Society For Gynecologic Investigation. 6: 32-40. DOI: 10.1177/107155769900600108 |
0.513 |
|
| 1999 |
Berek J, Bertelsen K, du Bois A, Brady M, Carmichael J, Eisenhauer E, Gore M, Grenman S, Hamilton T, Hansen S, Harper P, Horvath G, Kaye S, Lück H, Lund B, et al. Advanced epithelial ovarian cancer: 1998 consensus statements Annals of Oncology. 10: S87-S92. DOI: 10.1016/s0923-7534(20)31491-5 |
0.331 |
|
| 1999 |
Hamilton T, Berek J, Kaye S. Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future? Annals of Oncology. 10: S69-S73. DOI: 10.1016/S0923-7534(20)31488-5 |
0.486 |
|
| 1999 |
Kaye S, Eisenhauer E, Hamilton T. New non-cytotoxic approaches to ovarian cancer Annals of Oncology. 10: S65-S68. DOI: 10.1016/S0923-7534(20)31487-3 |
0.372 |
|
| 1998 |
Johnson SW, Ferry KV, Hamilton TC. Recent insights into platinum drug resistance in cancer. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 1: 243-54. PMID 16904407 DOI: 10.1016/S1368-7646(98)80005-8 |
0.404 |
|
| 1998 |
Wan XS, Hamilton TC, Ware JH, Donahue JJ, Kennedy AR. Growth inhibition and cytotoxicity induced by Bowman-Birk inhibitor concentrate in cisplatin-resistant human ovarian cancer cells Nutrition and Cancer. 31: 8-17. PMID 9682243 DOI: 10.1080/01635589809514672 |
0.378 |
|
| 1998 |
Calvert P, Yao KS, Hamilton TC, O'Dwyer PJ. Clinical studies of reversal of drug resistance based on glutathione Chemico-Biological Interactions. 111: 213-224. PMID 9679556 DOI: 10.1016/S0009-2797(98)00008-8 |
0.396 |
|
| 1998 |
Hamilton TC, Johnson SW, Godwin AK. Molecular biology of gynecologic malignancies. Cancer Treatment and Research. 95: 103-14. PMID 9619281 DOI: 10.1007/978-1-4615-5447-9_2 |
0.58 |
|
| 1997 |
Abdollahi A, Roberts D, Godwin AK, Schultz DC, Sonoda G, Testa JR, Hamilton TC. Identification of a zinc-finger gene at 6q25: A chromosomal region implicated in development of many solid tumors Oncogene. 14: 1973-1979. PMID 9150364 DOI: 10.1038/Sj.Onc.1201034 |
0.574 |
|
| 1996 |
Dyck HG, Hamilton TC, Godwin AK, Lynch HT, Maines-Bandiera S, Auersperg N. Autonomy of the epithelial phenotype in human ovarian surface epithelium: Changes with neoplastic progression and with a family history of ovarian cancer International Journal of Cancer. 69: 429-436. PMID 8980241 DOI: 10.1002/(Sici)1097-0215(19961220)69:6<429::Aid-Ijc1>3.0.Co;2-6 |
0.594 |
|
| 1996 |
Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, Boente MP, Lynch HT, Hamilton TC. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. Journal of the National Cancer Institute. 88: 1810-20. PMID 8961970 DOI: 10.1093/Jnci/88.24.1810 |
0.55 |
|
| 1996 |
Rose GS, Tocco LM, Granger GA, DiSaia PJ, Hamilton TC, Santin AD, Hiserodt JC. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat American Journal of Obstetrics and Gynecology. 175: 593-599. PMID 8828419 DOI: 10.1053/Ob.1996.V175.A73595 |
0.363 |
|
| 1996 |
O'Dwyer PJ, Szarka CE, Yao KS, Halbherr TC, Pfeiffer GR, Green F, Gallo JM, Brennan J, Frucht H, Goosenberg EB, Hamilton TC, Litwin S, Balshem AM, Engstrom PF, Clapper ML. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. The Journal of Clinical Investigation. 98: 1210-7. PMID 8787684 DOI: 10.1172/Jci118904 |
0.366 |
|
| 1996 |
Boente MP, Hamilton TC, Godwin AK, Buetow K, Kohler MF, Hogan WM, Berchuck A, Young RC. Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment. Current Problems in Cancer. 20: 83-137. PMID 8731031 |
0.444 |
|
| 1996 |
O'Dwyer PJ, Perez RP, Yao KS, Godwin AK, Hamilton TC. Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines Biochemical Pharmacology. 52: 21-27. PMID 8678904 DOI: 10.1016/0006-2952(96)00131-1 |
0.559 |
|
| 1996 |
Johnson SW, Shen DW, Pastan I, Gottesman MM, Hamilton TC. Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines Experimental Cell Research. 226: 133-139. PMID 8660948 DOI: 10.1006/Excr.1996.0211 |
0.424 |
|
| 1996 |
Johnson SW, Lissy NA, Miller PD, Testa JR, Ozols RF, Hamilton TC. Identification of zinc finger mRNAs using domain-specific differential display Analytical Biochemistry. 236: 348-352. PMID 8660516 DOI: 10.1006/Abio.1996.0178 |
0.32 |
|
| 1996 |
Schröder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC, Ozols RF. Glutathione and drug resistance Cancer Investigation. 14: 158-168. PMID 8597901 DOI: 10.3109/07357909609018891 |
0.476 |
|
| 1996 |
O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 14: 249-56. PMID 8558205 DOI: 10.1200/Jco.1996.14.1.249 |
0.316 |
|
| 1995 |
Perez RP, Johnson SW, Handel LM, O'Dwyer PJ, Hamilton TC. Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells Gynecologic Oncology. 58: 312-318. PMID 7672697 DOI: 10.1006/Gyno.1995.1236 |
0.41 |
|
| 1995 |
Godwin AK, Miller PD, Getts LA, Jackson K, Sonoda G, Schray KJ, Testa JR, Hamilton TC. Retroviral-like sequences specifically expressed in the rat ovary detect genetic differences between normal and transformed rat ovarian surface epithelial cells. Endocrinology. 136: 4640-9. PMID 7664684 DOI: 10.1210/Endo.136.10.7664684 |
0.518 |
|
| 1995 |
Auersperg N, Maines-Bandiera S, Booth JH, Lynch HT, Godwin AK, Hamilton TC. Expression of two mucin antigens in cultured human ovarian surface epithelium: Influence of a family history of ovarian cancer American Journal of Obstetrics and Gynecology. 173: 558-565. PMID 7645635 DOI: 10.1016/0002-9378(95)90282-1 |
0.547 |
|
| 1995 |
O’Dwyer PJ, Hamilton TC, Yao K, Tew KD, Ozols RF. Modulation of Glutathione and Related Enzymes in Reversal of Resistance to Anticancer Drugs Hematology/Oncology Clinics of North America. 9: 383-396. DOI: 10.1016/S0889-8588(18)30100-X |
0.307 |
|
| 1994 |
Chin-Hsiang C, Fung-Fang W, Hamilton TC. Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells Molecular and Cellular Endocrinology. 99: 11-19. PMID 8187952 DOI: 10.1016/0303-7207(94)90140-6 |
0.386 |
|
| 1994 |
Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, Hamilton TC. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines Biochemical Pharmacology. 47: 689-697. PMID 8129746 DOI: 10.1016/0006-2952(94)90132-5 |
0.555 |
|
| 1993 |
Johnson SW, Ozols RF, Hamilton TC. Mechanisms of drug resistance in ovarian cancer Cancer. 71: 644-649. PMID 8420689 DOI: 10.1002/Cncr.2820710224 |
0.413 |
|
| 1993 |
Godwin AK, Testa JR, Hamilton TC. The biology of ovarian cancer development Cancer. 71: 530-536. PMID 8420673 DOI: 10.1002/Cncr.2820710207 |
0.624 |
|
| 1993 |
Perez RP, Godwin AK, Handel LM, Hamilton TC. A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines European Journal of Cancer. 29: 395-399. PMID 8398340 DOI: 10.1016/0959-8049(93)90394-U |
0.54 |
|
| 1993 |
Ozols RF, O'Dwyer PJ, Hamilton TC. Clinical reversal of drug resistance in ovarian cancer Gynecologic Oncology. 51: 90-96. PMID 8244181 DOI: 10.1006/Gyno.1993.1252 |
0.431 |
|
| 1993 |
Lidor YJ, O'Briant KC, Xu FJ, Hamilton TC, Ozols RF, Bast RC. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action Journal of Clinical Investigation. 92: 2440-2447. PMID 8227359 DOI: 10.1172/Jci116851 |
0.335 |
|
| 1993 |
Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer. 71: 1571-80. PMID 8094321 DOI: 10.1002/Cncr.2820710424 |
0.438 |
|
| 1992 |
O'Dwyer PJ, Hamilton TC, Young RC, LaCreta FP, Carp N, Tew KD, Padavic K, Comis RL, Ozols RF. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. Journal of the National Cancer Institute. 84: 264-7. PMID 1734088 DOI: 10.1093/Jnci/84.4.264 |
0.357 |
|
| 1992 |
Perez RP, Handel LM, Hamilton TC. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor Gynecologic Oncology. 46: 82-87. PMID 1634144 DOI: 10.1016/0020-7292(93)90204-A |
0.489 |
|
| 1992 |
Perez RP, Perez KM, Handel LM, Hamilton TC. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines. Cancer Chemotherapy and Pharmacology. 29: 430-4. PMID 1568285 DOI: 10.1007/Bf00684842 |
0.439 |
|
| 1992 |
Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, Hamilton TC. Spontaneous transformation of rat ovarian surface epithelial cells: Association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer Journal of the National Cancer Institute. 84: 592-601. PMID 1556770 DOI: 10.1093/Jnci/84.8.592 |
0.62 |
|
| 1992 |
Hamilton T. Ovarian cancer, Part I: Biology Current Problems in Cancer. 16: 5-57. PMID 1547635 DOI: 10.1016/0147-0272(92)90047-R |
0.51 |
|
| 1992 |
Godwin AK, Perez RP, Johnson SW, Hamaguchi K, Hamilton TC. Growth regulation of ovarian cancer Hematology/Oncology Clinics of North America. 6: 829-841. PMID 1500388 DOI: 10.1016/S0889-8588(18)30312-5 |
0.591 |
|
| 1992 |
Louie KG, Hamilton TC, Shoemaker RH, Young RC, Ozols RF. Evaluation of in vitro drug screening leads using experimental models of human ovarian cancer. Investigational New Drugs. 10: 73-8. PMID 1500268 DOI: 10.1007/Bf00873120 |
0.421 |
|
| 1992 |
Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas Proceedings of the National Academy of Sciences of the United States of America. 89: 9267-9271. PMID 1409633 DOI: 10.1073/Pnas.89.19.9267 |
0.509 |
|
| 1992 |
Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis Proceedings of the National Academy of Sciences of the United States of America. 89: 3070-3074. PMID 1348364 DOI: 10.1073/Pnas.89.7.3070 |
0.605 |
|
| 1991 |
Perez RP, O'Dwyer PJ, Handel LM, Ozols RF, Hamilton TC. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines International Journal of Cancer. 48: 265-269. PMID 2019469 DOI: 10.1002/Ijc.2910480219 |
0.445 |
|
| 1990 |
Schilder RJ, Hall L, Monks A, Handel LM, Fornace AJ, Ozols RF, Fojo AT, Hamilton TC. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer International Journal of Cancer. 45: 416-422. PMID 2307530 DOI: 10.1002/Ijc.2910450306 |
0.478 |
|
| 1990 |
Perez RP, Hamilton TC, Ozols RF. Resistance to alkylating agents and cisplatin: Insights from ovarian carcinoma model systems Pharmacology and Therapeutics. 48: 19-27. PMID 2274575 DOI: 10.1016/0163-7258(90)90015-T |
0.459 |
|
| 1990 |
Ozols RF, O'Dwyer PJ, Hamilton TC, Young RC. The role of glutathione in drug resistance. Cancer Treatment Reviews. 17: 45-50. PMID 2092870 DOI: 10.1016/0305-7372(90)90015-8 |
0.305 |
|
| 1989 |
Hamilton TC, Lai GM, Rothenberg ML, Fojo AT, Young RC, Ozols RF. Mechanisms of resistance to cisplatin and alkylating agents Cancer Treatment and Research. 48: 151-169. PMID 2577136 DOI: 10.1007/978-1-4613-1601-5_10 |
0.437 |
|
| 1989 |
Nash JD, Ozols RF, Smyth JF, Hamilton TC. Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro American Journal of Obstetrics and Gynecology. 73: 1009-1016. PMID 2542854 DOI: 10.1097/00006250-198906000-00021 |
0.425 |
|
| 1989 |
Lai GM, Ozols RF, Young RC, Hamilton TC. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines Journal of the National Cancer Institute. 81: 535-539. PMID 2493524 DOI: 10.1093/Jnci/81.7.535 |
0.376 |
|
| 1989 |
Nash J, Hall L, Ozols R, Smyth J, Hamilton T. Estrogenic regulation and growth factor expression in human ovarian cancer (HOC) in vitro Gynecologic Oncology. 32: 127. DOI: 10.1016/0090-8258(89)91000-7 |
0.405 |
|
| 1988 |
Foster BJ, Grotzinger KR, McKoy WM, Rubinstein LV, Hamilton TC. Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate Cancer Chemotherapy and Pharmacology. 22: 147-152. PMID 3409446 DOI: 10.1007/Bf00257313 |
0.399 |
|
| 1988 |
Lai GM, Ozols RF, Smyth JF, Young RC, Hamilton TC. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer Biochemical Pharmacology. 37: 4597-4600. PMID 3144285 DOI: 10.1016/0006-2952(88)90325-5 |
0.422 |
|
| 1987 |
Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochemical Pharmacology. 36: 147-53. PMID 3801051 DOI: 10.1016/0006-2952(87)90392-3 |
0.451 |
|
| 1987 |
Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE, Young RC. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients Journal of Clinical Oncology. 5: 641-647. PMID 3559654 DOI: 10.1200/Jco.1987.5.4.641 |
0.397 |
|
| 1987 |
Holt JA, Waggoner SE, Lee EY, Hubby MM, Hamilton TC. Serum CA 125 and survival of mice inoculated with ovarian carcinoma and treated with antiestrogen, estrogen, or progestin. Gynecologic Oncology. 27: 282-93. PMID 3476351 DOI: 10.1016/0090-8258(87)90248-4 |
0.302 |
|
| 1987 |
Fojo A, Hamilton TC, Young RC, Ozols RF. Multidrug resistance in ovarian cancer Cancer. 60: 2075-2080. PMID 3308067 DOI: 10.1002/1097-0142(19901015)60:8+<2075::Aid-Cncr2820601521>3.0.Co;2-F |
0.48 |
|
| 1987 |
Hamilton TC, Ozols RF, Longo DL. Biologic therapy for the treatment of malignant common epithelial tumors of the ovary Cancer. 60: 2054-2063. PMID 2443236 DOI: 10.1002/1097-0142(19901015)60:8+<2054::Aid-Cncr2820601518>3.0.Co;2-0 |
0.432 |
|
| 1986 |
Louie KG, Hamilton TC, Winker MA, Behrens BC, Tsuruo T, Klecker RW, McKoy WM, Grotzinger KR, Myers CE, Young RC. Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. Biochemical Pharmacology. 35: 467-72. PMID 3947382 DOI: 10.1016/0006-2952(86)90221-2 |
0.474 |
|
| 1986 |
Batist G, Behrens BC, Makuch R, Hamilton TC, Katki AG, Louie KG, Myers CE, Ozols RF. Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro. Biochemical Pharmacology. 35: 2257-9. PMID 3827990 DOI: 10.1016/0006-2952(86)90601-5 |
0.338 |
|
| 1986 |
Manetta A, Satyaswaroop PG, Hamilton T, Ozols R, Mortel R. Radioimaging of human ovarian carcinoma xenograft in nude mice Gynecologic Oncology. 28: 292-299. PMID 3678978 DOI: 10.1016/0090-8258(87)90175-2 |
0.343 |
|
| 1986 |
Behrens BC, Hamilton TC, Louie KG, Grotzinger KR, McKoy WM, Tsuruo T, Young RC, Ozols RF. Activity of tricyclic nucleoside 5'-phosphate in model systems of human ovarian cancer. Investigational New Drugs. 4: 295-304. PMID 3583641 DOI: 10.1007/Bf00173502 |
0.435 |
|
| 1986 |
Louie KG, Hamilton TC, Behrens BC, Grotzinger KR, McKoy WM, Myers CE, Young RC, Ozols RF. Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma. Cancer Chemotherapy and Pharmacology. 18: 153-6. PMID 3466726 DOI: 10.1007/Bf00262286 |
0.466 |
|
| 1986 |
Tsuruo T, Hamilton TC, Louie KG, Behrens BC, Young RC, Ozols RF. Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin. Japanese Journal of Cancer Research. 77: 941-945. DOI: 10.20772/Cancersci1985.77.9_941 |
0.476 |
|
| 1985 |
Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochemical Pharmacology. 34: 2583-6. PMID 4040369 DOI: 10.1016/0006-2952(85)90551-9 |
0.436 |
|
| 1985 |
Pirker R, FitzGerald DJP, Hamilton TC, Ozols RF, Laird W, Frankel AE, Willingham MC, Pastan I. Characterization of immunotoxins active against ovarian cancer cell lines Journal of Clinical Investigation. 76: 1261-1267. PMID 3930572 DOI: 10.1172/Jci112082 |
0.397 |
|
| 1984 |
Hamilton TC, Behrens BC, Louie KG, Ozols RF. Induction of progesterone receptor with 17 beta-estradiol in human ovarian cancer. The Journal of Clinical Endocrinology and Metabolism. 59: 561-3. PMID 6746867 DOI: 10.1210/Jcem-59-3-561 |
0.339 |
|
| 1984 |
Rogan AM, Hamilton TC, Young RC, Klecker RW, Ozols RF. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (New York, N.Y.). 224: 994-6. PMID 6372095 DOI: 10.1126/Science.6372095 |
0.481 |
|
| 1984 |
Hamilton TC, Young RC, Ozols RF. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Seminars in Oncology. 11: 285-298. DOI: 10.5555/Uri:Pii:0093775484901337 |
0.326 |
|
| Show low-probability matches. |